Follow-on Biologics

Research and Markets: Israel Pharmaceuticals and Healthcare Report Q1 2010 [Press Release]
Business Wire | 6 days 11 hours 38 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/ab4c9e/israel_pharmaceuti) has announced the addition of the "Israel Pharmaceuticals and Healthcare Report Q1 2010" report to their offering.

Mesynthes Obtains U.S. FDA 510(k) Clearance for Endoform Dermal Template [Press Release]
Business Wire | 6 days 17 hours 43 minutes ago
Mesynthes, a privately held regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company?s Endoform Dermal Template?. Endoform, a proprietary extracellular matrix biomaterial, provides a unique biologic template for tissue regeneration.

CRN Questions Accuracy of Herbal Products Article [Press Release]
PRNewswire | 7 days 8 hours 7 minutes ago
WASHINGTON, Feb. 1 /PRNewswire-USNewswire/ -- In response to the publication of a review article, "Use of Herbal Products and Potential Interactions in Patients with Cardiovascular Disease," published in the Journal of the American College of Cardiology, the Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement industry, issued the following statement:

PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine [Press Release]
PRNewswire | 7 days 9 hours 56 minutes ago
ANNAPOLIS, Md., Feb. 1 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has submitted a White Paper in response to the Broad Agency Announcement (Solicitation Number: BAA-BARDA-09-34) issued by the Biomedical Advanced Research and Development Authority (BARDA) for the Advanced Research and Development of Chemical, Biological, Radiological and Nuclear Medical Co...

Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer [Press Release]
PRNewswire | 7 days 14 hours 44 minutes ago
ABBOTT PARK, Ill. and CASTRES, France, Feb. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.  cMet protein plays a role in the progression of a range of solid tumors including, prostate, lung and gastric cancers and ...

New Plan for Generic Drugs in Europe - Pharmaceutical Technology [Press Release]
PharmTech.com | 7 days 16 hours 21 minutes ago
The Director-General of the European Generic medicines Association has reiterated the group's Vision 2015 plan.

Benlysta Will Garner Sales of More Than $500 Million in 2018 in the Systemic Lupus Erythematosus Drug Market [Press Release]
PRNewswire | 7 days 17 hours 43 minutes ago
WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market. If approved, Benlysta will be the first agent to launch for systemic lupus erythematosus in mor...

Ipsen s Fourth Quarter and Full Year 2009 Sales [Press Release]
Business Wire | 8 days 43 minutes ago
Regulatory News: